MedTrace Logo

Safety and Efficacy of Fenofibrate as a Treatment for Huntington's Disease

NCT03515213 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2023-09-28

Study results available
· View outcomes & findings →

Summary

The purpose of this research study is to study the safety and efficacy of fenofibrate, an FDA-approved drug for high cholesterol and/or elevated triglycerides (fats), as a treatment for Huntington's disease (HD). Subjects who meet the entry criteria will be randomized (3:1) to either 145mg of fenofibrate or placebo.

Conditions

  • Huntington Disease

Interventions

DRUG

Fenofibrate

145mg of fenofibrate

DRUG

Placebo

Placebo

Sponsors & Collaborators

  • University of California, Irvine

    lead OTHER

Principal Investigators

  • Neal Hermanowicz, MD · University of California, Irvine

  • Leslie Thompson, PhD · University of California, Irvine

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-04-27
Primary Completion
2021-08-31
Completion
2021-08-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03515213 on ClinicalTrials.gov